We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center
News

Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center

Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center
News

Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Angion Biomedica Corp. has signed an exclusive world-wide licensing option with Memorial Sloan Kettering Cancer Center in New York City (MSKCC) for a novel vaccine platform developed by Professor Samuel Danishefsky.

Professor Danishefsky is the Kettering Chair and Director of the Laboratory for Bioorganic Chemistry at the Sloan-Kettering Institute and the Centennial Professor of Chemistry at Columbia University.

The vaccine platform enables presentation of multiple carbohydrate antigens on a single synthetic scaffold and has been shown to trigger an in vivo immune response to multiple oncology related targets. The vaccine scaffold can be customized for various clinical indications and represents a major advance for immunotherapy.

A Phase I clinical trial is scheduled to start early in 2009.
Advertisement